KISSEI PHARMACEUTICAL CO.,LTD.(4547) News

Notice Concerning Disposal of Treasury Shares as Restricted Stock for Employee Shareholding Association

Consolidated Financial Results for the Nine Months Ended December 31, 2025 [Japanese GAAP]

Notice Concerning Revisions to Dividend Forecast (Implementation of Commemorative Dividend for the 80th Anniversary of the

Supplementary Explanatory Materials on Financial Results for the Nine Months Ended December 31, 2025

KISSEI PHARMA, Oct-Dec (3Q) Ordinary Profit Increases by 11%, Current Fiscal Year Dividend Revised Upward by 40 Yen

Marketing Authorization Approval in Japan for Yselty Tablets 100mg, an Oral GnRH Antagonist, Indicated for Uterine Fibroids

Notice of Change to Scheduled Date to Commence Dividend Payments

Financial Briefing for the Second Quarter (Interim) of the Fiscal Year Ended March 31, 2026 (Fiscal 2025)

Notice Concerning Revisions to Financial Results Forecast

Consolidated Financial Results for the Six Months Ended September 30, 2025 [Japanese GAAP]

Supplementary Explanatory Materials on Financial Results for the Six Months Ended September 30, 2025

KISSEI PHARMA, Ordinary Profit Forecast for the Fiscal Year Loss to Narrow

Linzagolix Approved for Marketing in Taiwan

Licensing Agreement for "Linzagolix" with Searchlight Pharma in Canada

Notice Regarding Sale of Investment Securities (Result)

Licensing Agreement with Viridian Therapeutics for "Veligrotug" and "VRDN-003" in Treatment of Thyroid Eye Disease

Consolidated Financial Results for the Three Months Ended June 30, 2025 [Japanese GAAP]

KISSEI PHARMA, Ordinary Profit Forecast for the Fiscal Year Revised Downward to a Loss

Supplementary Explanatory Materials on Financial Results for the Three Months Ended June 30, 2025

Notice Concerning Revisions to Financial Results Forecast and Recording of Extraordinary Income